Skip to main content

Table 1 Characteristics of the observational studies included in the systematic review with meta-analysis

From: The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis

First author name Country Gender Year Sample size Age Treatment Dose Measure Lean mass (kg) App. lean mass (kg) Method of BC assay Pre-DAS-28 Post-DAS-28
Tournadre [23] France M/F 2017 21 57.8 ± 10.5 Tocilizumab
12 months
NI Lean mass
App. lean mass
Baseline: 42.1 (± 11.1)
Final: 43.2 (±11.3)
Baseline: 17.7 (± 5.4)
Final: 18.7 (± 5.6)
DEXA 4.94 ± 1.25 2.8 ± 1.5
Toussirot [22] France M/F 2020 107 56.6 ± 13.5 Tocilizumab
12 months
8 mg/kg (monthly) Lean mass Baseline: 40.76 (± 8.4)
Final: 42.11 (± 8.9)
DEXA 4.93 ± 1.3 2.3 ± 1.3
Ferraz-Amaro [24] Spain M/F 2011 16 50.8 ± 14.6 Anti-TNF
12 months
Varied Lean mass Baseline: 53.7 (NI)
Final: 50.5 (NI)
BIA 5.58 ± 0.87 2.89 ± 1.37
Metsios [25] United Kingdom M/F 2007 20 61.1 ± 6.8 Anti-TNF
3 months
NI Lean mass Baseline: 50.9 (± 12.7)
Final: 51.1 (± 12.5)
BIA 5.66 ± 0.7 3.59 ± 0.7
Chikugo [26] Japan F 2018 4 55.3 ± 19.5 Tofacitinib
6 months
NI App. lean mass Baseline: NI
Final: 20.4 (± 4.0)
BIA 5.1 ± 0.8 NI
Al Khayyat [27] Italy F 2021 20 65 ± 12.9 Rituximab
18 months
Eight infusions of 500 mg~1 g Lean mass
App. lean mass
Baseline: 39.94 ± 8.74
Final: 38.64 ± 8.19
Baseline: 16.21 ± 3.60
Final: 17.84 ± 4.03
DEXA NI NI
Vial [28] France Male/Female 2021 83 58.5 ± 10.8 Biologic DMARD (TNFi and non-TNFi) NI Lean mass TNFi
Baseline: 49.6 ± 10.8
Final: 50.7 ± 11.3
Non TNFi
Baseline: 47.7 ± 11.0
Final: 47.4 ± 10.9
DEXA 4.21 ± 1.1 NI
  1. BIA bioimpedance, DEXA dual-energy X-ray absorptiometry, NI not informed, TNF tumor necrosis factor, TNFi TNF inhibitor, BC body composition, M male, F female